These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 18823299)

  • 1. Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib.
    Schwartz JI; Agrawal NG; Wehling M; Musser BJ; Gumbs CP; Michiels N; De Smet M; Wagner JA
    Br J Clin Pharmacol; 2008 Dec; 66(6):811-7. PubMed ID: 18823299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
    Agrawal NG; Porras AG; Matthews CZ; Rose MJ; Woolf EJ; Musser BJ; Dynder AL; Mazina KE; Lasseter KC; Hunt TL; Schwartz JI; McCrea JB; Gottesdiener KM
    J Clin Pharmacol; 2003 Mar; 43(3):268-76. PubMed ID: 12638395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist.
    Denker AE; Morelli G; Vessey LK; Li S; Yuan J; Dunbar S; Lewis NM; Taggart W; Wagner JA
    Adv Ther; 2009 Feb; 26(2):230-40. PubMed ID: 19219408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib.
    Hynninen VV; Olkkola KT; Neuvonen PJ; Laine K
    Eur J Clin Pharmacol; 2009 Jan; 65(1):89-95. PubMed ID: 18777173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers.
    Agrawal NG; Porras AG; Matthews CZ; Woolf EJ; Miller JL; Mukhopadhyay S; Neu DC; Gottesdiener KM
    J Clin Pharmacol; 2001 Oct; 41(10):1106-10. PubMed ID: 11583479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers.
    Weber P; Lettieri JT; Kaiser L; Mazzu AL
    Clin Ther; 1999 Sep; 21(9):1563-75. PubMed ID: 10509851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects.
    Vaz da Silva M; Costa R; Soares E; Maia J; Falcão A; Almeida L; Soares da Silva P
    Fundam Clin Pharmacol; 2009 Aug; 23(4):509-14. PubMed ID: 19500154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of effect of antacids on single-dose pharmacokinetics of etoricoxib.
    Schwartz JI; Agrawal NG; Kher UA; DeSmet M; Cavanaugh PF; Guillaume M; Ebel DL; Merschman SA; Wagner JA
    J Clin Pharmacol; 2007 Oct; 47(10):1342-6. PubMed ID: 17656618
    [No Abstract]   [Full Text] [Related]  

  • 9. Voriconazole does not affect the steady-state pharmacokinetics of digoxin.
    Purkins L; Wood N; Kleinermans D; Nichols D
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):45-50. PubMed ID: 14616413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.
    Agrawal NG; Matthews CZ; Mazenko RS; Woolf EJ; Porras AG; Chen X; Miller JL; Michiels N; Wehling M; Schultz A; Gottlieb AB; Kraft WK; Greenberg HE; Waldman SA; Curtis SP; Gottesdiener KM
    J Clin Pharmacol; 2004 Oct; 44(10):1125-31. PubMed ID: 15342613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants.
    Schwartz J; Hunt T; Smith WB; Wong P; Larson P; Crumley T; Mehta A; Gottesdiener K; Agrawal N
    J Clin Pharmacol; 2009 Jul; 49(7):807-15. PubMed ID: 19443681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic interaction of sparfloxacin and digoxin.
    Johnson RD; Dorr MB; Hunt TL; Conway S; Talbot GH
    Clin Ther; 1999 Feb; 21(2):368-79. PubMed ID: 10211539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers.
    Schwartz JI; De Smet M; Larson PJ; Verbesselt R; Ebel DL; Lins R; Lens S; Porras AG; Gertz BJ
    J Clin Pharmacol; 2001 Jan; 41(1):107-12. PubMed ID: 11144988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilomilast: pharmacokinetic and pharmacodynamic interactions with digoxin.
    Zussman BD; Kelly J; Murdoch RD; Clark DJ; Mbchb ; Schubert C; Collie H
    Clin Ther; 2001 Jun; 23(6):921-31. PubMed ID: 11440291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
    Liu F; Vessey L; Wenning L; Connolly S; Buckland M; Johnson-Levonas AO; Denker A; Wagner JA; Lai E
    J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis.
    Schwartz JI; Agrawal NG; Wong PH; Miller J; Bachmann K; Marbury T; Hoelscher D; Cavanaugh PF; Gottesdiener K
    J Clin Pharmacol; 2009 Oct; 49(10):1202-9. PubMed ID: 19783714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of etoricoxib in patients with renal impairment.
    Agrawal NG; Matthews CZ; Mazenko RS; Kline WF; Woolf EJ; Porras AG; Geer LA; Wong PH; Cho M; Cote J; Marbury TC; Moncrief JW; Alcorn H; Swan S; Sack MR; Robson RA; Petty KJ; Schwartz JI; Gottesdiener KM
    J Clin Pharmacol; 2004 Jan; 44(1):48-58. PubMed ID: 14681341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lacosamide on the steady-state pharmacokinetics of digoxin: results from a phase I, multiple-dose, double-blind, randomised, placebo-controlled, crossover trial.
    Cawello W; Mueller-Voessing C; Andreas JO
    Clin Drug Investig; 2014 May; 34(5):327-34. PubMed ID: 24634110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases.
    El Miedany Y; Youssef S; Ahmed I; El Gaafary M
    Am J Gastroenterol; 2006 Feb; 101(2):311-7. PubMed ID: 16454836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.
    Smulders RA; Kuipers ME; Krauwinkel WJ
    Br J Clin Pharmacol; 2006 Aug; 62(2):210-7. PubMed ID: 16842396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.